Sensus Healthcare (NASDAQ:SRTS) Releases Quarterly Earnings Results, Misses Expectations By $0.41 EPS

Sensus Healthcare (NASDAQ:SRTS) posted its quarterly earnings results on Thursday. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.41), FiscalAI reports. Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 20.30%. The business had revenue of $2.29 million during the quarter, compared to analyst estimates of $4.60 million.

Here are the key takeaways from Sensus Healthcare’s conference call:

• Negative Sentiment: Second-quarter revenue fell to $2.3 million from $7.3 million year over year, while adjusted EBITDA was negative $3.0 million and net loss widened to $8.7 million, including a $5.7 million deferred-tax valuation allowance.
• Positive Sentiment: Management said financing delays prevented recognition of eight additional units in Q2, but those systems were subsequently approved and sold at an expected average selling price near $250,000; the related revenue is expected in Q3.
• Positive Sentiment: The company reported a stronger pipeline following education around new CPT codes, with increasing interest from independent practices, larger physician groups, and health systems. Management expects unit volume to rise sequentially, targeting more than 20 units in both Q3 and Q4.
• Positive Sentiment: Recurring-revenue initiatives are gaining traction, with the Fair Deal Agreement and outright purchases running at roughly a 50/50 mix. Sensus Link adoption is expanding among new and existing customers and is viewed as a high-margin software growth opportunity.
• Positive Sentiment: International expansion, particularly in Australia, New Zealand, China, and Hong Kong, is generating increased interest, while a proposed 26% increase in the relevant hospital physician fee schedule could further support SRT economics.

Sensus Healthcare Stock Performance

Shares of SRTS stock opened at $2.86 on Friday. The stock has a fifty day moving average price of $2.95 and a 200 day moving average price of $3.65. The stock has a market cap of $47.08 million, a PE ratio of -3.04 and a beta of 1.10. Sensus Healthcare has a 1 year low of $2.66 and a 1 year high of $5.49.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on SRTS shares. Wall Street Zen cut Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Lake Street Capital cut their price target on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a report on Friday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a research note on Friday, July 17th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $5.83.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. XTX Topco Ltd acquired a new position in shares of Sensus Healthcare during the 4th quarter worth $77,000. Rothschild Wealth LLC purchased a new position in Sensus Healthcare during the 4th quarter valued at about $500,000. Greenline Wealth Management LLC purchased a new position in Sensus Healthcare during the 4th quarter valued at about $513,000. Ingalls & Snyder LLC acquired a new position in Sensus Healthcare during the fourth quarter worth about $219,000. Finally, State Street Corp lifted its holdings in shares of Sensus Healthcare by 5.2% in the fourth quarter. State Street Corp now owns 69,252 shares of the company’s stock valued at $276,000 after purchasing an additional 3,400 shares in the last quarter. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.